Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:4905
Name pancreatic carcinoma
Definition A pancreas cancer that derives_from epithelial cells located_in the exocrine pancreas.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer pancreatic cancer pancreatic carcinoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
BRAF V487_P492delinsA LXH 254 pancreatic carcinoma sensitive detail...
BRAF V487_P492delinsA Trametinib pancreatic carcinoma sensitive detail...
BRAF V487_P492delinsA Encorafenib pancreatic carcinoma decreased response detail...
BRAF V487_P492delinsA Sorafenib pancreatic carcinoma sensitive detail...
BRAF V487_P492delinsA Ulixertinib pancreatic carcinoma predicted - sensitive detail...
BRAF V487_P492delinsA LXH 254 + Trametinib pancreatic carcinoma predicted - sensitive detail...
BRAF V487_P492delinsA Sorafenib + Trametinib pancreatic carcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01174121 Phase II Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer Recruiting USA 0
NCT01537107 Phase I Sirolimus + Vismodegib Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery Completed USA 0
NCT01663272 Phase I Cabozantinib + Gemcitabine A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer Completed USA 0
NCT01954732 Phase I Metformin Metformin Hydrochloride in Treating Patients With Pancreatic Cancer That Can be Removed by Surgery Withdrawn 0
NCT02009449 Phase I Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors Active, not recruiting USA 0
NCT02268825 Phase Ib/II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Phase I/IIA Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers Terminated USA 0
NCT02807844 Phase Ib/II MCS110 + Spartalizumab Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies Completed USA | ITA | FRA | ESP | DEU | BEL 5
NCT02847000 Phase 0 Decitabine + Tetrahydrouridine p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer Completed USA 0
NCT02930902 Phase I Paricalcitol + Pembrolizumab Gemcitabine + Nab-paclitaxel + Paricalcitol + Pembrolizumab Preoperative Pilot Study to Assess Safety and Immunological Effect of Pembrolizumab (Keytruda) in Combination With Paricalcitol With or Without Chemotherapy in Patients With Resectable Pancreatic Cancer Completed USA 0
NCT02960594 Phase I INO-1400 + INO-9012 INO-1400 hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Completed USA 0
NCT03752398 Phase I Izuralimab A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) Active, not recruiting USA 0
NCT03825289 Phase I Hydroxychloroquine + Trametinib Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer (THREAD) Recruiting USA 0
NCT03849469 Phase I Pembrolizumab + XmAb22841 XmAb22841 A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) Completed USA 0
NCT04386057 Phase II Hydroxychloroquine + LY3214996 LY3214996 LY3214996 +/- HCQ in Pancreatic Cancer Completed USA 0
NCT04431258 Phase Ib/II ABTL0812 + Fluorouracil + Irinotecan + Oxaliplatin Fluorouracil + Irinotecan + Oxaliplatin ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study (PanC-ASAP) Completed USA | FRA | ESP 1
NCT04735796 Phase I LM-102 Study of LM-102 in Subjects in Advanced Tumors Terminated USA 0
NCT04752215 Phase I BI 765049 + Ezabenlimab BI 765049 A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface Recruiting USA | CAN 0
NCT05001516 Phase Ib/II TPX-4589 Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors Completed USA 0
NCT05042128 Phase II Gemcitabine + Nab-paclitaxel CEND-1 + Gemcitabine + Nab-paclitaxel The ASCEND Study: Gemcitabine and Nab-Paclitaxel With CEND-1 or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma (ASCEND) Active, not recruiting NZL | AUS 0
NCT05143970 Phase I IPH5301 IPH5301 + Paclitaxel + Trastuzumab A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (CHANCES) Recruiting FRA 0
NCT05831995 Phase I ABM-168 Safety and Effectiveness of ABM-168 in Adults With Advanced Solid Tumors. Recruiting USA 0
NCT06242470 Phase I MGC026 A Study of MGC026 in Participants With Advanced Solid Tumors Recruiting USA 0